Coherus Oncology (CHRS) Other Operating Expenses (2019 - 2026)

For the trailing twelve months through Jun 30, 2026, Other Operating Expenses at Coherus Oncology was $15.82 million, up 37.3% year-over-year; for FY2025, it came in at $13.81 million, up 58.3% from FY2024.

• Annual Other Operating Expenses shows a five-year compound annual growth rate of -18.2% (FY2020 to FY2025).
• In prior years, Coherus Oncology's Other Operating Expenses was $8.73 million in FY2024 (-94.5%), $158.99 million in FY2023 (+126.9%), $70.08 million in FY2022 (+21.7%) and $57.59 million in FY2021 (+52.9%).
• The Q2 2026 figure stands as the highest quarterly Other Operating Expenses since Q4 2023.
• On a year-over-year basis, Other Operating Expenses has increased in each of the last six quarters, with growth averaging 17.0% over the last eight quarters.
• The strongest year-over-year quarter for Other Operating Expenses in the past five years was Q4 2023, with growth of 495.5%; the weakest was Q4 2024, with a decline of 96.7%.
• According to Business Quant data, Other Operating Expenses for the three prior quarters was $3.81 million (Q1 2026), $4.05 million (Q4 2025) and $3.72 million (Q3 2025).